高级搜索

术前动脉灌注化疗治疗局部晚期胃癌的系统评价

刘锐锋, 王小琦, 王小虎, 张春林

刘锐锋, 王小琦, 王小虎, 张春林. 术前动脉灌注化疗治疗局部晚期胃癌的系统评价[J]. 肿瘤防治研究, 2012, 39(09): 1098-1106. DOI: 10.3971/j.issn.1000-8578.2012.09.012
引用本文: 刘锐锋, 王小琦, 王小虎, 张春林. 术前动脉灌注化疗治疗局部晚期胃癌的系统评价[J]. 肿瘤防治研究, 2012, 39(09): 1098-1106. DOI: 10.3971/j.issn.1000-8578.2012.09.012
Liu Ruifeng, Wang Xiaoqi, Wang Xiaohu, Zhang Chunlin. Preoperative Intra-arterial Infusion Chemotherapy for Locally Advanced Gastric Cancer:A Systematic Review[J]. Cancer Research on Prevention and Treatment, 2012, 39(09): 1098-1106. DOI: 10.3971/j.issn.1000-8578.2012.09.012
Citation: Liu Ruifeng, Wang Xiaoqi, Wang Xiaohu, Zhang Chunlin. Preoperative Intra-arterial Infusion Chemotherapy for Locally Advanced Gastric Cancer:A Systematic Review[J]. Cancer Research on Prevention and Treatment, 2012, 39(09): 1098-1106. DOI: 10.3971/j.issn.1000-8578.2012.09.012

术前动脉灌注化疗治疗局部晚期胃癌的系统评价

基金项目: 甘肃省科技厅科技创新团队资助项目(09877CA009)
详细信息
    作者简介:

    刘锐锋(1983-),男,硕士,住院医师,主要从事消化道肿瘤的放射及综合治疗研究

    通讯作者:

    王小琦,E-mail: liurf@yahoo.cn

  • 中图分类号: R735.2

Preoperative Intra-arterial Infusion Chemotherapy for Locally Advanced Gastric Cancer:A Systematic Review

  • 摘要: 目的 评价术前动脉灌注化疗与全身静脉化疗或单独手术治疗局部晚期胃癌的有效性和安全性。方法计算机检索PubMed(2000年1月—2011年5月)、EMBASE(2000年1月—2011年5月),Cochrane Library(2011年第4期),中国生物医学文献数据库(CBM,2000年1月—2011年5月)、中国期刊全文数据库(CJFD,2000年1月~2011年5月)和中文科技期刊全文数据库(CSJD,2000年1月—2011年5月),同时从参考文献中追溯查找。按照纳入标准,全面搜集有关术前动脉灌注化疗(IAIC+S)与全身静脉化疗(IVC+S)或单独手术(S)治疗局部晚期胃癌方面的临床对照试验,无论是否采用随机对照研究。按照Cochrane系统评价方法,由两位研究者独立提取资料和进行质量评价,并用RevMan5.1软件进行统计分析。结果共纳入7个研究,792例患者。Meta分析结果显示,IAIC+S组与IVC+S组相比,根治性切除率差异有统计学意义,RR(95%CI)为1.70(1.41~2.05),姑息性切除率差异无统计学意义,RR(95%CI)为0.37(0.04~3.13)。在治疗应答率中,病理学应答率、临床应答率RR(95%CI)分别为1.33(0.96~1.84)和1.32(0.50~3.44)。化疗不良反应中,除胃肠反应RR(95%CI)为0.52(0.28~0.94),骨髓抑制、肝功能损害和其他不良反应方面,两组间差异均无统计学意义,RR(95%CI)分别为0.64(0.38~1.07)、0.88(0.29~2.64)、0.93(0.53~1.61)。术后并发症方面,吻合口瘘、腹腔感染和切口感染,两组间差异均无统计学意义,RR(95%CI)分别为2.46(0.49~12.34)、0.53(0.05~5.57)、2.10(0.20~22.26)。IAIC+S组与S组相比,根治性切除和姑息性切除率方面两组间差异均存在统计学意义,RR(95%CI)分别为1.30(1.16~1.45)和 0.58(0.42~0.79)。1、2、3和5年生存率间差异均有统计学意义,RR(95%CI)分别为1.11(1.03~1.20)、1.36(1.09~1.69)、1.70(1.35~2.14)和1.85(1.30~2.65)。术后并发症方面,无论吻合口瘘、腹腔感染和切口感染方面两组间差异均无统计学意义,RR(95%CI)分别为0.78(0.27~2.28)、0.65(0.16~2.65)、1.15(0.43~3.10)。结论术前动脉灌注化疗是一种有效且安全的治疗方法。在手术切除率、总生存率、化疗不良反应以及并发症指标上,都显示出动脉灌注化疗的优势。

     

    Abstract: Objective To assess the clinical efficacy and safety of preoperative intra-arterail infusion chemothrapy(IAIC+S)+surgery(S) versus Preoperative intravenous chemotherapy+S(IVC+S) or S alone for locally advanced gastric carcinoma. Methods PubMed(January,2000 to May,2011),EM BASE(January,2000 to May,2011),Cochrane Library(Issue 4,2011),Chinese Biomedical Literature Database(January,2000 to May,2011),China Journal Full text Database(January,2000 to December,2007), and Chinese Scientific Journals Full text Database(January,2000 to December,2007) were searched for relevant original published in any date.We also track back to the references to collect trails.Inclusion criteria were as follows:clinical controlled trails regardless of randomization were reported in English or Chinese.Two reviewers extracted data and assessed the quality of included trials independently.The RevMan 5.1 software was used for statistical analysis. Results Seven studies involving 792 patients were included.Meta-analysis showed that,between(IAIC+S) and (IVC+S),there was significant difference in radical resection rate,and the pooled RR(95%CI)was 1.70(1.41~2.05).But in response rate,complications of postoperation and chemotherapy side effects,they all had no statistical difference.Between(IAIC+S) and S alone,RRs of radical and palliative resection rates(95%CI) were 1.30(1.16~1.45)and 0.58(0.42~0.79)respectively.All 1-year,3-year,4-year,5-year and overall survival had statistical signicance,with 1.11(1.03~1.20),1.36(1.09~1.69),1.70(1.35~2.14)and 1.85(1.30~2.65),respectively.In postoperative complications,RRs (95%CI) of anastomotic leakage,abdominal infection and wound infection were 0.78(0.27~2.28),0.65(0.16~2.65) and 1.15(0.43~3.10)respectively,without statistical differences. Conclusion This study suggested that IAIC is an effective and safety method compared with IVC or S alone in improving radical resection rate and survival rate for locally advance gastric cancer.But in view of the poor quality of included studies,our result was needed to be furtherly confirmed.

     

  • [1] Janunger KG, Hafstrm L, Nygren P, et al. A systematic overview of chemotherapy effects in gastric cancer[J]. Acta Oncol,2001,40(2-3):309-26.
    [2] Rougier P, Lasser P, Ducreux M,et al. Preoperative chemotherapy of locally advanced gastric cancer[J]. AnnOncol, 1994, 5(Suppl 3): 59-68.
    [3] He LF,Yang KH,Tian JH,et al. Meta analysis of clinical effectiveness of neoadjuvant chemotherapy for gastriccancer[J]. Ai Zheng, 2008, 27(4) : 407-12 .[ 贺岭风,杨克虎,田金徽,等. 胃癌新辅助化疗疗效的系统评价-Meta分析[J].癌症, 2008, 27( 4) : 407- 12.]
    [4] Kosaka T, Ueshige N, Sugaya J, et al. Evaluation of intra-arterial infusion chemotherapy   for advancedgastric cancer[J]. Gan To Kagaku Ryoho, 1998, 25(9): 1288-91.
    [5] Greene FL.American Joint Committee on Cancer(AJCC).Cancer Staging Manual[M]. 6th.New York:Springer,2002.
    [6] Juni P, Altman DG, Egger M. Assessing the quality of controlled clinical trials[J]. BMJ, 2001, 323(7303):42-6.
    [7] Ge LZ, Wu SG,Gong LP, et al. Treatment of Advanced Gastric Carcinoma by Gastric Artery InterventionChemoembolization Combined with Radical Cure Resection[J]. Zhong Liu Fang Zhi Yan Jiu,2007,34(4):300-2.[葛来增,吴仕光,龚立鹏,等.胃动脉介入化疗栓塞联合根治术治疗进展期胃癌[J]. 肿瘤防治研究, 2007, 34(4): 300-2.]
    [8] Fu WJ, Xue YJ,Tang D, et al.Comparison of preoperative intra-arterial and intravenous chemotherapy in theresectable advanced gastric cancer[J]. Wu Jing Yi Xue Yuan Xue Bao, 2010, 19(1): 35-8.[傅文杰,薛彦俊,汤东,等.术前动脉介入化疗与全身化疗对进展期胃癌手术切除率的对比研究[J]. 武警医学院学报, 2010, 19(1): 35-8.]
    [9] Ye ZB,Ma T, Xi WQ,et al. Clinical Study on Neoadjuvant Chemotherapy for Late Stage Gastric Carcinoma[J].Wai Ke Li Lun Yu Shi Jian, 2002, 7(5): 376-8.[叶正宝, 马韬,奚文崎,等. 晚期胃癌新辅助化疗的初步临床研究[J].外科理论与实践,2002,7(5): 376-8.]
    [10] Bian YH, Cao H, Yu FR, et al. Effects of preoperative arterial infusion chemotherapy with oxaliplatin and5-Fu for patients with advanced gastric cancer[J].Zhongguo Pu Tong Wai Ke Za Zhi, 2009, 18(9): 955-9.[卞育海,曹晖, 郁丰荣, 等. 奥沙利铂联合5-Fu术前动脉化疗对进展期胃癌的临床疗效[J]. 中国普通外科杂志, 2009, 18(9): 955-9.]
    [11] Ji XC, Wang WX, Yuan Y. Effect of preoperative arterial chemotherapy on resectable rate and radical rate ofthe patients with advanced gastric cancer[J].Xian Dai Shi Yong Yi Xue, 2005,17(7):403-4.[季晓春,汪闻夕,袁谊.术前动脉化疗对进展期胃癌手术切除率的影响[J]. 现代实用医学, 2005, 17(7): 403-4.]
    [12] Li D, Wu PS. Comparative clinical study on preoperative intra-arterial infusion chemotherapy for advancedgastric cancer [J]. Zhongguo Ai Zheng Za Zhi, 2010, 20(4): 290-4.[李东,吴萍山.术前动脉介入化疗治疗进展期胃癌的病例对照研究[J].中国癌症杂志,2010,20(4): 290-4.]
    [13] Yu FR, Cao H, Bian YH, et al. Effects of preoperative regional intra-arterial infusion chemotherapy forpatients with advanced gastric cancer [J].Wai Ke Li Lun Yu Shi Jian,2008, 13(1): 44-7.[郁丰荣,曹晖,卞育海,等.术前区域性动脉灌注化疗治疗进展期胃癌的临床研究[J].外科理论与实践, 2008, 13(1): 44-7.]
    [14] Liu FK. The interventional therapy for advanced gastric cancer before and after operation[J]. ZhongguoShi Yong Wai Ke Za Zhi, 2001, 21(7): 403-4. [刘福坤.进展期胃癌手术前后介入治疗[J].中国实用外科杂志,2001,21(7):403-4.]
    [15] Tokairin Y, Maruyama M, Baba H, et al. Pharmacokinetics of subselective arterial infusion chemotherapy[J]. Gan To Kagaku Ryoho, 2001, 28(11): 1795-8.
    [16] Wu P, Zhu ZG, Ye ZB, et al. Experimental study on pharmacokinetics of floxuridine administeredpreoperatively via the left gastric artery[J]. Wai Ke Li Lun Yu Shi Jian, 2004, 9(2): 135-9.[吴鹏,朱正纲,叶正宝,等.5-氟尿嘧啶-2′-脱氧核苷经胃左动脉介入灌注后的药代动力学实验研究[J]. 外科理论与实践, 2004, 9(2): 135-9.]
    [17] Ensminger WD. Intrahepatic arterial infusion of chemotherapy: pharmacologic principles[J]. Semin Oncol,2002, 29(2):119-25.
    [18] Shchepotin I,Evans S,Chorny V,et al. Preoperative superselective intraarterial chemotherapy in the combinedtreatment of gastric-carcinoma [J]. Oncol Rep, 1995, 2(3): 473-9.
    [19] Vanhoefer U, Rougier P, Wilke H,et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusionalfluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research andTreatment of Cancer Gastrointestinal Tract Cancer Cooperative Group[J]. J Clin Oncol,2000,18(14): 2648-57.
    [20] Ross P, Nicolson M,Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, andprotracted venous-infusion fluorouracil(PVI 5-Fu) With epirubicin, cisplatin, and PVI 5-Fu in advancedesophagogastric cancer [J].J Clin Oncol,2002, 20(8): 1996-2004.
    [21] Okines AF, Norman AR, McCloud P, et al. Meta-analysis of the REAL-2 and ML17032 trials: evaluatingcapecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for thetreatment of advanced oesophago-gastric cancer [J]. Ann Oncol, 2009, 20(9): 1529-34.
    [22] Takahashi I, Kakeji Y, Emi Y, et al. S-1 in the treatment of advanced and recurrent gastric cancer: currentstate and future prospects[J]. Gastric Cancer, 2003, 6(Suppl 1): 28-33.
    [23] Van Cutsem E,Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plusfluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a reportof the V325 study group[J]. J Clin Oncol, 2006, 24(31): 4991-7.
计量
  • 文章访问数:  2209
  • HTML全文浏览量:  22
  • PDF下载量:  665
  • 被引次数: 0
出版历程
  • 收稿日期:  2012-01-02
  • 修回日期:  2012-03-26
  • 刊出日期:  2012-09-24

目录

    /

    返回文章
    返回
    x 关闭 永久关闭